Clinical Trials Browser

Phase 2 × Pleural Effusion, Malignant × Cetuximab × Clear all

NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant